Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 153 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug B Clear all

Conditions: Hypercholesterolemia
Interventions: CIVI 007; Drug
Lead sponsor: Civi Biopharma, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Jacksonville, Florida • Port Orange, Florida • Indianapolis, Indiana + 4 more

Conditions: Hearing Loss, Depression
Interventions: Phonak Audeo B-R 90 hearing aid device (Active), Duloxetine or escitalopram, Audeo B-R 90 hearing aid device (Sham); Device · Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 60 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer Disease, Dementia, Dementia, Vascular, Pain
Interventions: hydrocodone/APAP w placebo PRN, hydrocodone/APAP, placebo with hydrocodone/APAP PRN; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 55 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 3
States / cities: Tuscaloosa, Alabama

Conditions: Glioblastoma Multiforme
Interventions: VBI-1901, Carmustine, Lomustine; Biological · Drug
Lead sponsor: VBI Vaccines Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 12
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 8 more

Conditions: Myelodysplastic Syndromes, Cytopenia
Interventions: Elritercept; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 11
States / cities: Hot Springs, Arkansas • Duarte, California • Miami, Florida + 8 more

Conditions: Infections, Meningococcal
Interventions: MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine; Combination Product · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 50 Years
Enrollment: 1,440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more

Conditions: Breast Neoplasms
Interventions: Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin, Gemcitabine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 46
States / cities: Hot Springs, Arkansas • Cerritos, California • Long Beach, California + 35 more

Conditions: HIV Infections
Interventions: VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 34
States / cities: Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more

Conditions: Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Interventions: PRI-724; Drug
Lead sponsor: Prism Pharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Atlanta, Georgia • Worcester, Massachusetts • Albuquerque, New Mexico + 3 more

Conditions: Lymphoma
Interventions: filgrastim, chemotherapy, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV-1 Infection
Interventions: B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Ft. Pierce, Florida • Gainesville, Florida + 7 more

Conditions: Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL), Hodgkin's Lymphoma
Interventions: Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative), Fludarabine, Melphalan, ATG (Reduced Intensity); Drug
Lead sponsor: Targazyme, Inc.; Industry
Eligibility: 1 Year to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 4
States / cities: La Jolla, California • Cleveland, Ohio • Houston, Texas + 1 more

Conditions: Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, High Grade Gliomas, Medulloblastoma Recurrent, Ependymoma Recurrent, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, Brain Tumor Recurrent
Interventions: NeuroNavigation-Guided Focused Ultrasound (NgFUS), Lumason, Nivolumab; Device · Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Years to 25 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Placebo (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B), Placebo (Part B), CK-2017357 (Part B); Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: San Francisco, California • Jacksonville, Florida • Kansas City, Kansas + 6 more

Conditions: Chronic Insomnia
Interventions: Low Dose Drug A, Low Dose Drug B, High Dose Drug A, High Dose Drug B, SOM001-A, SOM001-B, SOM001-C, SOM001-D, Placebo; Drug
Lead sponsor: Somnum Pharma Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer's Disease, Dementia
Interventions: EVP-6124; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 56
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 53 more

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: SAR445088 (IV), SAR445088 (SC); Drug
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Fairway, Kansas + 2 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Lamivudine, Sorbitol; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV
Interventions: CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702), Aluminum Hydroxide Suspension (Alum), ACU-026-001-1 (labeled as empty LNP); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee

Conditions: Endometriosis Related Pain
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 43
States / cities: Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more

Conditions: Advanced Solid Tumors
Interventions: Golvatinib, Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
Interventions: Iomab-B, Conventional Care, HCT; Drug · Procedure
Lead sponsor: Actinium Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 22
States / cities: Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more

Conditions: Multiple Myeloma
Interventions: BB2121, CC-220, BMS-986405; Biological · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Jacksonville, Florida + 9 more

Conditions: Glioblastoma Multiforme
Interventions: Amgen 386, Bevacizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • Worcester, Massachusetts + 2 more

Search by objective public record fields.

Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy

Treating Hearing Loss to Improve Mood and Cognition in Older Adults

Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Low- or Intermediate-Grade Non-Hodgkin's Lymphoma

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Study of Oral SOM001 as a Safe and Effective Treatment for Adults With Chronic Insomnia in a Randomized, Controlled, Dose-finding Study

Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025

Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

Amgen 386 for Recurrent Glioblastoma